Aclarion, Inc., a healthcare technology company leveraging biomarkers and AI algorithms to help physicians identify the location of chronic low back pain, has announced several milestones in the development and commercialization of its Nociscan technology. The company is making strides toward establishing Nociscan as a standard of care decision support tool in the treatment of chronic low back pain, which costs Americans an estimated $134 billion annually.
One of the most significant achievements is the coverage decision by three of the four largest private insurance payers in the UK to cover Nociscan. This development is crucial for driving broader physician adoption and predictable revenue. Aclarion is now expanding its sales and marketing efforts in London to capitalize on these coverage decisions.
In the United States, Aclarion has partnered with ten prominent Key Opinion Leader (KOL) surgeons to assist in gaining traction and reimbursement. These KOLs are participating in clinical data collection, engaging with insurance companies, and advocating for coverage decisions. The company has also entered into a strategic partnership with ATEC, a major spine implant company, to leverage their physician relationships and expand Aclarion’s KOL advocacy strategy.
Aclarion has executed multiple commercial agreements providing access to Nociscan at MRI scanners in key markets such as New York, New Jersey, Arizona, Colorado, and Michigan. The company is also expanding into the personal injury and workers compensation market, partnering with Dr. Justin Kubeck to educate attorneys and judges on the potential benefits of Nociscan for high-stakes cases.
To support its efforts in gaining payer coverage, Aclarion is focused on generating favorable clinical and economic data. The company has published peer-reviewed articles based on a pivotal study showing improved and durable clinical outcomes when Nociscan results were used in surgical treatment decisions. Additionally, an economic analysis commissioned by Aclarion concluded that the use of Nociscan could save the US healthcare system nearly half a billion dollars annually.
Aclarion has launched CLARITY, a prospective, randomized, multi-center trial comparing outcomes of patients undergoing surgery for chronic discogenic back pain with and without the use of Nociscan in the decision-making process. The company expects this study to provide compelling data that will lead to coverage decisions from major insurance providers and endorsements from spine societies.
The company’s intellectual property position has also been strengthened, with 23 issued US patents, 17 issued international patents, and 12 pending patent applications. Recent patents have expanded Aclarion’s position in using AI analysis techniques for spectroscopy data and identifying bacterial biomarkers associated with pain.
As Aclarion continues to make progress, investors can expect further announcements regarding peer-reviewed evidence publications, additional commercial agreements, and expanded payer coverage decisions. The company’s efforts to establish Nociscan as a standard of care in chronic low back pain diagnosis and treatment represent a potential shift in the approach to this widespread and costly health issue.
This news story relied on a press release distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Aclarion’s Nociscan AI Technology Gains Traction in Chronic Low Back Pain Diagnosis.